
BIBLIOGRAFÍA

1. **AIDS epidemic update: 2004. ONUSIDA/OMS. Organización Mundial de la Salud. Consulta. Enero 2005. ISBN 92-8-173392-X: 1-38**
2. **Mandana Khalili, Brian W. Behm. Hepatitis C in the setting of HIV co-infection. Microbes and Infection. 2002 Oct; 4(12):1247-1251.Review**
3. **The Situation of the AIDS epidemic:2004. ONUSIDA/OMS. Organización Mundial de la Salud. UNAIDS. Agosto 2004. ISBN 92 9173 392: 1-35**
4. **Epidemiología del VIH/SIDA en México en el año 2003. Secretaría de Salud y Centro Nacional para la prevención y control del VIH/SIDA. Nov. 2003: 1-50**
5. **Weekty epidemiological record. World Health Organization. Febrery 2000**
6. **Hepatitis C: Epidemiology Prevalence of HCV. National Center for Infectious Diseases. 2004: 1-45**
7. **Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 2001;313(3): 451-64.**
8. **Laurence J. Coinfection with hepatitis viruses and HIV: good and bad news. AIDS Patient Care STDS 2001;15:599-602.**
9. **Maier IF, Wu GY. Hepatitis C and HIV co-infection: a review. World J Gastroenterol 2002;8:577-579.**
10. **Dewhurst, Steve. VIH-1: Biología molecular. Journal of Clinical Microbiology. 1999. Vol. 37 No. 7.**
11. **Fuente C, Santiago F, Deng L, et al. Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation**

-
- signals. *BMC Biochem.* 2002;3 (1): 1-14
12. Wu Y. HIV-1 gene expression: lessons from provirus and non-integrated DNA. *Retrovirology* 2004;1: 1-13
 13. Gómez-Cordero I, Álvarez-García M. Biología y métodos diagnósticos del virus de la hepatitis C. *Rev Biomed.* 2003;14: 253-268
 14. Kato N. Molecular virology of hepatitis C virus. *Acta Med. Okayama.* 2001;55: 133-159
 15. Choo Q-L, Richman KH, Han JH et al. Genetic organization and diversity of the hepatitis C virus. *Proc Natl Acad Sci USA* 1992;89: 2451-2455
 16. Buck J, Purcell RH, Miller RH. Sequence analysis of the 5' noncoding region of hepatitis C virus. *Proc Natl Acad Sci USA* 1992;89: 4942-4946
 17. Pestova RV, Shatsky IN, Fletcher SP et al. A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. *Genes Dev* 1998;12: 67-83
 18. Sreevatsan S, Bookout JB, Ringpis FM et al. Algorithmic approach to high-throughput molecular screening for alpha interferon-resistant genotypes in hepatitis C patients. *J Clin Microbiol* 1998;36: 1895-1901
 19. Yamada N, Tanihara KJ, Takada A et al. Genetic organization and diversity of the 3' noncoding region of the hepatitis C virus genome. *Virology* 1996;2: 955-968
 20. Grakoui A, Wychowski C, Lin C et al. Expression and identification of hepatitis C virus polyprotein cleavage products. *J Virol* 1993;67: 1385-1395

-
21. Zhu NL, Khoshanan A, Schneider R *et al.* Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. *J Virol* 1998;72: 3691-3697
22. Lin C, Lindenbach BD, Pragai BM *et al.* Processing in the hepatitis C virus E2-NS2 region: Identification of p7 and two distinct E2-specific products with different C termini. *J Virol* 1994;68: 5063-5073
23. Ralston R, Thudium K, Berger K *et al.* Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. *J Virol* 1993;67: 6753-6761
24. Kato N, Ootsuyama Y, Tanaka T *et al.* Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. *Virus Res* 1992;22: 107-123
25. Kato N, Ootsuyama Y, Sekiya H *et al.* Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. *J Virol* 1994;68: 4776-4784
26. Farci P, Shimoda A, Wong D *et al.* Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. *Proc Natl Acad Sci USA* 1996;93: 15394-15399
27. Santolini E, Pacini L, Fipaldini C *et al.* The NS2 protein of hepatitis C virus is a transmembrane polypeptide. *J Virol* 1995;69: 7461-7471
28. Gale MJJ, Korth MJ, Tang NM *et al.* Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein

-
- kinase by the non-structural 5A protein. *Virology* 1997;230: 217-227
29. Yamashita T, Kaneko S, Shirota Y *et al.* RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. *J Biol Chem* 1998;273: 15479-15486
 30. Thursz M. Genetic susceptibility in infectious diseases. *Biotechnol Genet Eng Rev* 2000;17: 253-64.
 31. McNicholl JM., Cuenco KT. Host genes and infectious diseases. HIV, other pathogens, and a public health perspective. *Am J Prev Med* 1999;16: 141-54.
 32. McNicholl JM, Downer MV, Udhayakumar VF, *et al.* Host-pathogen interactions in emerging and re-emerging infectious diseases: a genomic perspective of tuberculosis, malaria, HIV infection, hepatitis B and cholera. *Annu Rev Public Health* 2000;21: 15-46.
 33. Kaslow RA, McNicholl JM. Genetic determinants of HIV-1 infection and its manifestations. *Proc Assoc Am Physicians* 1999;111: 299-307.
 34. Dragic t. An overview of the determinants of CCR5 and CXCR4 co-receptor function. *J Gen Virol* 2001;82: 1807-14.
 35. Moore JP, Trkola AF, Dragic T. Co-receptors for HIV-1 entry. *Curr Opin Immunol* 1997;9: 551-62.
 36. Trkola AF, Dragic TF, Arthos JF, *et al.* CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. *Nature* 1996;384: 184-7.
 37. Dragic TF, Litwin VF, Allaway GP, *et al.* HIV-1 entry into CD4+ cells is

-
- mediated by the chemokine receptor CC-CKR-5. *Nature* 1996;381:667-673.
38. Murphy PM. Chemokine receptors: structure, function and role in microbial pathogenesis. *Cytokine Growth Factor Rev* 1996;7: 47-84.
 39. Samson MF, Libert FF, Doranz BJ, *et al.* Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. *Nature* 1996;382: 722-5.
 40. Rana S, Besson G, Cook D *et al.* Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the $\Delta ccr5$ mutation. *J Virol.* 1997;71: 3219-3227
 41. Agrawal L, Lu X, Qingwen J, *et al.* Role for CCR5 Delta32 protein in resistance to R5, R5X4, and X human immunodeficiency virus type 1 in primary CD4+ cells. *J Virol.* 2004; 78(5): 2277-87
 42. Venkatesan SF, Petrovic AF, Van Ryk DIF, *et al.* Reduced cell surface expression of CCR5 in CCR5 Delta 32 heterozygotes is mediated by gene dosage, rather than by receptor sequestration. *J Bio Chem* 2002;277: 2287-301.
 43. Samson MF, Soularue PF, Vassart GF, Parmentier M. The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3. *Genomics* 1996;36: 522-6.
 44. Samson MF, LaRosa GF, Libert FF, *et al.* The second extracellular loop of

-
- CCR5 is the major determinant of ligand specificity. *J Biol Chem* 1997;272: 21934-21941.
45. Paxton WA, Martin SR, Tse D, *et al.* Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. *Nat Med.* 1996;2(4): 412-417
 46. Kupfer B, Kaiser R, Brackmann HH, *et al.* Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene. *AIDS.*1999;13(9): 1025-1028
 47. Kuipers H, Workman C, Dyer W, *et al.* An HIV-1-infected individual homozygous for the CCR5 D32 allele and the SDF-1 34A allele. *AIDS.*1999;13(3): 433-434
 48. Huang Y, Paxton WA, Wolinsky SM, *et al.* The role of a mutant CCR5 allele in HIV-1 transmission and disprogression. *Nat Med.* 1996;2(11): 1240-1243
 49. Balotta C, Bagnarelli P, Violin M, *et al.* Homozygous delta 32 deletion of the CCR-5 chemokine receptor in an HIV-1-infected patient. *AIDS.* 1997;11(10): F67-F71
 50. Wu L, Paxton WA, Kassam N, *et al.* CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, *in vitro.* *J Exp Med.* 1997;185: 1681-1692
 51. Ansari-Lari MA, Liu XM, Metzker ML, Rut AR, Gibbs RA. The extent of genetic variation in the CCR5 gene. *Nat Genet* 1997;16: 221-222.
 52. Martinson JJ, Hong LF, Karanickolas RF, Moore JP, Kostrikis LG. Global

-
- distribution of the CCR2-64/CCR5-59653T HIV-1 disease-protective haplotype. *AIDS* 2000;14: 483-489.
53. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. *Nat Genet* 1997;16: 100-103.
54. Woitas RP, Ahlenstiel GF, Iwan AF, *et al.* Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. *Gastroenterology* 2002;122: 1721-1728.
55. Flint M, Maidens C, Loomis-Price LD, *et al.* Characterization of hepatitis C virus E_s glycoprotein interaction with a putative cellular receptor, CD81. *J Virol* 1999;73: 6235-6244.
56. Hennig BJ, Hellier SF, Frodsham AJ, *et al.* Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. *Genes Immun* 2002;3: 359-367.
57. Gerri RF, Crancee JM, Grain DF, *et al.* Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. *J Med Virol* 2002;68: 206-215.
58. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. *Proc Natl Acad Sci USA* 1999;96: 12766-12771.
59. Laurence J. Potential roles for chemokine receptor CCR5 in the pathobiology of hepatitis C infection. *Gastroenterology* 2002;122: 2069-2072.

-
60. Germl RF, Crance JM, Garin DF, Zarski JP, Drouet E. [Receptors for hepatitis C virus: update data]. *Gastroenterol Clin Biol* 2001;25: 1011-1015.
61. Shi SF, Polyak SJ, Tu HF, Taylor DR, *et al.* Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. *Virology* 2002; 292:198-210.
62. Shi SF, Lai MM. Hepatitis C viral RNA: challenges and promises. *Cell Mol Life Sci.* 2001;58: 1276-1295.
63. Wozniak MA, Itzhaki RF, Faragher EB, *et al.* Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. *Hepatology* 2002;36:456-463.
64. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 1987;162: 156-159.
65. Rivas-Estilla AM, Sánchez LV, O Matsui, Campollo O, Armendariz-Borunda J, Segura J and A Panduro. Identification of Hepatitis C virus (HCV) genotypes in infected patients from the West of Mexico. *Hepatology Research* 1998;12: 121-130.
66. A Mummidi S, Ahuja SS, *et al.* The human CC chemokine receptor 5 (CCR5) gene. *J Biol Chem.* 1997;272(49): 30662-30671.
67. A Liu R, Zhao X, *et al.* Functional analysis of the proximal CCR5 promoter. *AIDS Res Hum Retroviruses.* 1998.;14(17): 1509-1519
68. Carrington M, Kissner T, *et al.* Novel alleles of the chemokine-receptor

-
- gene CCR5. *Am J Hum Genet.* 1997;61: 1261-1267
69. Carrington M, Dean M, *et al.* Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. *Hum Mol Genet.* 1999;8: 1939-1945
70. Quillent C, Oberlin E, *et al.* HIV-1 resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. *Lancet.* 1998;351: 14-18
71. Kostrikis L, Neumann A, *et al.* A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American children. *J Virol.* 1999;73: 10264-10271
72. González E, Barnshad M, *et al.* Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. *PNAS.* 1999;96:12004-12009
73. Sambrook J, Russell D. *Molecular Cloning a Laboratory Manual.* 2002. Third Edition. Volume 1. Cold Spring Harbor Laboratory Press.
74. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. *Short Protocols in Molecular Biology.* 2002. Fifth Edition. Volume 1. Editorial Board.
75. *Management of Hepatitis C: 2002. NIH Consensus State Sci Statements.* 2002 Jun 10-12;19(3): 1-46
76. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. *Lancet.* 1991 May 11;337(8750):1158-1159
77. Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa

**Takayanagi M. Hepatitis C virus genotypes are not responsible for
developm serious liver disease. Dif Dis Sci. 1994 Feb;39(2):234-239**